Voxelotor
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 217 publications
GBT1118 voxelotor analog improves skeletal muscle function, phenotype and significantly reduced serum myopathy biomarker GDF15 in sickle cell disease mice.
Journal: Biochemical and biophysical research communications
Published: May 08, 2026
Discontinued therapies for sickle cell disease: status and future directions.
Journal: Expert opinion on investigational drugs
Published: April 20, 2026
In vitro effects of voxelotor on red blood cell senescence and rheological behavior in sickle cell anemia.
Journal: Blood cells, molecules & diseases
Published: March 26, 2026
Impact of voxelotor discontinuation on patients with sickle cell disease.
Journal: British journal of haematology
Published: March 04, 2026
Optimizing the right time to start sickle cell therapies.
Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025
Adherence, treatment utilization, clinical and economic outcomes of patients with sickle cell disease with recurrent vaso-occlusive crises treated with recently approved chronic therapies in the US.
Journal: Journal of comparative effectiveness research
Published: November 24, 2025
In Silico Post-screening of Anti-polymerization Agents to Treat Sickle Cell Disease.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
Low Use of FDA-Approved Medications for Sickle Cell Disease in Adults.
Journal: European journal of haematology
Published: October 23, 2025
Canine Mdr1 Knockout MDCK Cells Reliably Estimate Human Small Intestinal Permeability (Peff) and Fraction Absorbed (fa).
Journal: Molecular pharmaceutics
Published: September 07, 2025
Last Updated: 06/30/2026